glp-1 discovery Evolution of GLP‐1 Receptor Agonists for Diabetes Treatment Why GLP-1 drugs are changing

Structural Basis for GLP-1 Receptor Activation by LY3502970, an Orally Active Nonpeptide Agonist

If youre new to peptides, review our broader guide on how peptides support healthy aging

As treatment continues, some patients experience reductions in visceral abdominal fat together with improvements in body composition as part of a comprehensive medical program

CagriSema The combination of OW SC GLP-1 RA semaglutide and non-selective amylin RA cagrilintide (AM833) has been shown to demonstrate an additive effect on glucose regulation and weight loss as both GLP-1 RA and amylin analogs act on glucagon secretion, delay gastric emptying and mediate weight loss by acting through both distinct and overlapping neural satiety and reward pathways [47, 121]